<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04945603</url>
  </required_header>
  <id_info>
    <org_study_id>POGASH</org_study_id>
    <nct_id>NCT04945603</nct_id>
  </id_info>
  <brief_title>Poor Grade Aneurysmal Subarachnoid Hemorrhage Study Group</brief_title>
  <acronym>POGASH</acronym>
  <official_title>Poor Grade Aneurysmal Subarachnoid Hemorrhage Multicentric Study Group</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS San Raffaele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Azienda Ospedaliera Universitaria Integrata Verona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliero-Universitaria di Parma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>A.O. Ospedale Papa Giovanni XXIII</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ASL Taranto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale V. Fazzi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IRCCS San Raffaele</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicentric registry study in order to define outcome, predictors, treatment effects and&#xD;
      their modifiers in poor grade aneurysmal subarachnoid haemorrhage patients.&#xD;
&#xD;
      The search for outcome predictors is going to be subdivided into three main research areas:&#xD;
&#xD;
        1. outcome predictors in the emergency department (so called &quot;early brain injury phase&quot;).&#xD;
&#xD;
        2. outcome predictors in the neurocritical care unit (so called &quot;delayed brain injury&#xD;
           phase&quot;).&#xD;
&#xD;
        3. Treatment strategies. Two other areas of research are identified: delayed cerebral&#xD;
           ischemia (incidence, treatment, predictors, impact on outcome) and long term follow-up&#xD;
           (recent evidences suggest that there may be a non-negligible proportion of poor grade&#xD;
           subarachnoid hemorrhage patients who may benefit from substantial improvement at&#xD;
           long-term (after 6-12 months of follow-up).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 25, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2028</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Clinical Outcome</measure>
    <time_frame>6 months.</time_frame>
    <description>modified Rankin Scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Outcome</measure>
    <time_frame>12 months</time_frame>
    <description>modified Rankin Scale (mRS). Scale ranging from 0 (no symptoms) to 6 (dead) with higher scores indicating increasing neurological disability.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Long-Term clinical outcome</measure>
    <time_frame>12-60 months</time_frame>
    <description>modified Rankin Scale (mRS). Scale ranging from 0 (no symptoms) to 6 (dead)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delayed Cerebral Ischemia</measure>
    <time_frame>onset-30 days</time_frame>
    <description>Delayed Cerebral Ischemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rebleeding</measure>
    <time_frame>onset-48hours</time_frame>
    <description>Rebleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Complications</measure>
    <time_frame>onset-1 week</time_frame>
    <description>Treatment Complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decompressive Craniotomy</measure>
    <time_frame>onset-3 weeks</time_frame>
    <description>Incidence, strategy (primary or secondary), predictors and clinical impact</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventriculo-peritoneal shunt</measure>
    <time_frame>onset-4 weeks</time_frame>
    <description>Incidence, strategy (primary or secondary), predictors and clinical impact</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CSF drainage</measure>
    <time_frame>onset-3 weeks</time_frame>
    <description>Use of external ventricular drainage or lumbar drainage according to institutional protocol. Clinical impact.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volumetric analysis of intracranial bleeding</measure>
    <time_frame>onset-24hours</time_frame>
    <description>Volumetric analysis and distribution assessment of intracranial bleeding. Clinical impact</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volumetric analysis of delayed cerebral ischemia</measure>
    <time_frame>onset-3 weeks</time_frame>
    <description>Volumetric analysis and location assessment of delayed cerebral ischemia. Clinical impact</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Subarachnoid Hemorrhage, Aneurysmal</condition>
  <condition>Poor Grade Subarachnoid Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Poor Grade Subarachnoid Hemorrhage</arm_group_label>
    <description>All patients (prospective and retrospective) included will have to present a subarachnoid hemorrhage defined poor grade according to the WFNS scale due to the rupture of an intracranial aneurysm.&#xD;
The patients are managed according to both most recent international guidelines on the specific disease (Stroke, May 2012) and according to national and institutional guidelines/protocols.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard management according to international/national guidelines</intervention_name>
    <description>Standard management according to international/national guidelines. Observational study</description>
    <arm_group_label>Poor Grade Subarachnoid Hemorrhage</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All consecutive patients admitted to the emergency department because of aneurysmal&#xD;
        subarachnoid hemorrhage of poor grade (IV-V) according to the WFNS classification&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients admitted to the emergency department because of aneurysmal subarachnoid&#xD;
             hemorrhage of poor grade (IV-V) according to the WFNS classification.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients younger than 18 years old.&#xD;
&#xD;
          -  Pregnant or breast-feeding patients.&#xD;
&#xD;
          -  Aneurysmal subarachnoid hemorrhage due to trauma or vascular malformations other than&#xD;
             cerebral aneurysms.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Pietro Panni, P.I., M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neuroradiology, Department of Neurosurgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pietro Panni, P.I., M.D.</last_name>
    <phone>+393406311389</phone>
    <email>panni.pietro@hsr.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrea Falini, Professor of Neuroradiology</last_name>
    <phone>+39 0226432239</phone>
    <email>falini.andrea@hsr.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ASST Ospedale Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simone Piva, MD</last_name>
      <email>simone.piva@unibs.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Vito Fazzi</name>
      <address>
        <city>Lecce</city>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilio Lozupone, MD</last_name>
      <email>emilio.lozupone@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pietro Panni, P.I./MD</last_name>
      <phone>+393406311389</phone>
      <email>panni.pietro@hsr.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Parma</name>
      <address>
        <city>Parma</city>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edoardo Picetti, MD</last_name>
      <email>edoardopicetti@hotmail.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Agostino Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Santissima Annunziata</name>
      <address>
        <city>Taranto</city>
        <zip>74121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vittorio Semeraro, MD</last_name>
      <email>vittoriosemeraro@hotmail.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Integrata</name>
      <address>
        <city>Verona</city>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Feletti, Professor/MD</last_name>
      <email>alberto.feletti@univr.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 15, 2021</study_first_submitted>
  <study_first_submitted_qc>June 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2021</study_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS San Raffaele</investigator_affiliation>
    <investigator_full_name>Pietro Panni</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

